SCHEMBL1110482

SCHEMBL1110482

CC(C)(C)OC(=O)CN(c1cccc2c(C(=O)NCc3cccc(C(=O)N4CCN(C(=O)OC(C)(C)C)CC4)c3)cccc12)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TP53 P04637 2/20 0.40
STS P08842 4/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP2C19 P33261 1/20 0.36
LMNA P02545 2/20 0.35
POLB P06746 1/20 0.35
MAPK8 P45983 2/20 0.35
MAPK10 P53779 2/20 0.35
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
MAPT P10636 1/20 0.35
PTGER1 P34995 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110191 0.94 SMN1; SMN2 (0.46) SMN1; SMN2HTTNPSR1TP53STS
SCHEMBL12119357 0.92 HSD11B1 (0.40) SMN1; SMN2NPSR1TP53POLBALDH1A1
SCHEMBL1110172 0.90 POLB (0.38) SMN1; SMN2HTTNPSR1TP53STS
SCHEMBL12119657 0.87 PTGER1 (0.38) HTTMEN1KMT2ACYP2C19POLB
SCHEMBL12119184 0.87 F10 (0.39) HTTMEN1KMT2ACYP2C19PTGER1
SCHEMBL12119228 0.86 PTGER1 (0.38) HTTMEN1KMT2ACYP2C19ALDH1A1
SCHEMBL12119306 0.86 HSD11B1 (0.47) SMN1; SMN2HTTNPSR1MEN1KMT2A
SCHEMBL13658675 0.84 PTGER1 (0.39) HTTMEN1KMT2ACYP2C19ALDH1A1
SCHEMBL1110100 0.84 SMN1; SMN2 (0.44) SMN1; SMN2HTTNPSR1TP53STS
SCHEMBL12119303 0.83 PTGER1 (0.46) SMN1; SMN2HTTTP53KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 SMN1; SMN2 2627/4885HTT 2848/4885NPSR1 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.